Table 5 CAT total score on entry and throughout the study (per protocol set)
LABA/LAMA FDC (N = 292) | Triple therapy (N = 675) | p-value | |
|---|---|---|---|
Median CAT score (1st, 3rd quartile) | |||
Baseline visit | 21.0 (13.0, 23.0) | 20.0 (15.0, 25.0) | 0.008 |
Median CAT score, absolute change from baseline (1st, 3rd quartile) | |||
Visit 1 (after approx. 3 months) | − 1.0 (− 3.0 to 0.0) | − 1.0 (− 3.0 to 1.0) | 0.028 |
Visit 2 (after approx. 6 months) | − 2.0 (− 4.0 to 0.0) | − 1.0 (− 4.0 to 1.0) | 0.002 |
Visit 3 (after approx. 9 months) | − 2.0 (− 4.0 to 0.0) | − 1.0 (− 4.0 to 2.0) | 0.004 |
Visit 4 (after approx. 12 months) | − 2.0 (− 5.0 to 0.0) | − 1.0 (− 4.0 to 2.0) | 0.003 |
CAT score responders, n (%) | |||
Visit 1 (after approx. 3 months) | |||
Clinically relevant improvement | 124 (42.5) | 250 (37.0) | < 0.001 |
Clinically relevant worsening | 32 (11.0) | 149 (22.1) | |
Visit 2 (after approx. 6 months) | |||
Clinically relevant improvement | 156 (53.4) | 304 (45.0) | < 0.001 |
Clinically relevant worsening | 32 (11.0) | 155 (23.0) | |
Visit 3 (after approx. 9 months) | |||
Clinically relevant improvement | 166 (56.8) | 313 (46.4) | < 0.001 |
Clinically relevant worsening | 34 (11.6) | 173 (25.6) | |
Visit 4 (after approx. 12 months) | |||
Clinically relevant improvement | 170 (58.2) | 330 (48.9) | < 0.001 |
Clinically relevant worsening | 40 (13.7) | 172 (25.5) |